SEC Form 4 · accession 0000914475-15-000014

NEUROCRINE BIOSCIENCES INC · NBIX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Medical Officer

Period of report

Jan 8, 2015

Accepted (ET)

Jan 9, 2015 · 4:30 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000914475

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jan 8, 2015	M	20,000	$2.59	A	116,544	D
Common Stock	Jan 8, 2015	S	20,000	$27.11	D	96,544	D
Common Stock	Jan 8, 2015	M	20,000	$2.59	A	116,544	D
Common Stock	Jan 8, 2015	S	20,000	$27.11	D	96,544	D
Common Stock	Jan 8, 2015	M	15,000	$2.59	A	111,544	D
Common Stock	Jan 8, 2015	S	15,000	$27.50	D	96,544	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Incentive Stock Option^F2	$2.59	Jan 8, 2015	M	20,000	D	—	May 11, 2017	Common Stock	20,000	35,000	D
Incentive Stock Option^F2	$2.59	Jan 8, 2015	M	20,000	D	—	May 11, 2017	Common Stock	20,000	15,000	D
Incentive Stock Option^F2	$2.59	Jan 8, 2015	M	15,000	D	—	May 11, 2017	Common Stock	15,000	0	D

F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2The option was granted May 11, 2010 and vested in 36 equal monthly installments beginning June 11, 2010.